BackVerona Pharma Plc Overview

Verona Pharma Plc Other Current Liabilities

Verona Pharma Plc's other current liabilities is $47M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$46.79M
11.00% YoYΔ $4.64M vs prior year quarter

Peer trimmed avg / median

Loading

Verona Pharma Plc Other Current Liabilities History

Loading

Verona Pharma Plc vs. peers: Other Current Liabilities Comparison

Loading

Verona Pharma Plc Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Verona Pharma Plc (VRNA) FAQ

Verona Pharma Plc posts a other current liabilities of $47M as of June 2025. That compares with $42M in the prior-year period — up 11.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Verona Pharma Plc's other current liabilities was $42M. The latest reading is $47M — a 11.0% year-over-year increase (period ending June 2025). Use the history and growth charts on this page for a longer lookback.

Other Current Liabilities is one piece of Verona Pharma Plc's financial statement story. At $47M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for VRNA's other current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Verona Pharma Plc's other metric pages and overview cover the third.

Judging Verona Pharma Plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current liabilities easier to interpret. Start with $47M here, then scan peer and history charts to see if the gap is persistent.